Klin Padiatr 2011; 223(3): 138-141
DOI: 10.1055/s-0031-1275349
Original Article

© Georg Thieme Verlag KG Stuttgart · New York

Diagnosis and Treatment of Renal Cell Carcinoma in Children: A Report from the Polish Pediatric Rare Tumor Study Group

Diagnose und Therapie des Nierenzellkarzinoms bei Kindern: Ein Bericht der polnischen Arbeitsgruppe für seltene pädiatrische TumorenT. Stachowicz-Stencel1 , E. Bien1 , A. Balcerska1 , J. Godzinski2 , A. Synakiewicz1 , M. Perek-Polnik3 , A. Kurylak4 , W. Pietras5 , M. Kuzmicz6 , A. Mizia-Malarz7 , A. Rybczynska8 , J. Nurzynska-Flak9
  • 1Department of Pediatrics, Hematology, Oncology and Endocrinology, Medical University of Gdansk, Poland
  • 2Department of Pediatric Surgery, Marciniak Hospital, Wroclaw, Poland
  • 3Department of Oncology, The Children's Memorial Health Institute, Warsaw, Poland
  • 4Department of Oncology and Hematology, Medical University, Bydgoszcz, Poland
  • 5Department of Bone Marrow Transplantation, Oncology and Hematology, Medical University, Wroclaw, Poland
  • 6Department of Oncology and Hematology, Medical University, Bialystok, Poland
  • 7Department of Oncology and Hematology, Medical University, Katowice, Poland
  • 8Department of Oncology and Hematology, Medical University, Poznan, Poland
  • 9Department of Oncology and Hematology, Medical University, Lublin, Poland
Further Information

Publication History

Publication Date:
20 April 2011 (online)

Abstract

Background: Renal cell carcinoma (RCC) in children is rare, accounting for approximately 1.9–6% of all pediatric renal malignancies. The aim of this study was to transmit our experience in the treatment of RCC in Polish children.

Methods: Clinical data from 21 children (6.3–18 years old) with RCC treated between 1992 and 2009 at Polish pediatric oncological centers were analyzed.

Results: In 2 patients, RCC developed as a second malignancy after neuroblastoma or astrocytoma fibrillare, respectively. In 6 patients, initial diagnoses based on imaging studies were unilateral Wilms’ tumor, leading to preoperative chemotherapy. The remaining patients underwent surgery at the beginning of treatment. According to the AJCC/TNM staging system, 14 patients had stage I, 5-II, 1-III, and 1-IV. Nephrectomy was performed in 19 patients, heminephrectomy in one, and biopsy in another. Histopathological diagnoses were clear-cell RCC (18 patients), papillary RCC (2 patients), and chromophobe RCC (1 patient). 10 patients were treated with chemotherapy, with or without IL-2, INFα, and antiangiogenic agents. 2 patients died due to disease progression.

Conclusions: RCC in children is mostly operable at diagnosis, resulting in good prognosis. The role of adjuvant chemo- and immunotherapies is unclear. Neoadjuvant chemotherapy proven for children with Wilms' tumors is ineffective, but the delay in adequate therapy did not worsen the outcome if complete nephrectomy is done subsequently.

Zusammenfassung

Hintergrund: Das Nierenzellkarzinom (NCC) bei Kindern ist selten und beträgt 1,9–6% aller Nierentumoren des Kindes- und Jugendalters; hier werden die Erfahrungen der polnischen Arbeitsgruppe für seltene Tumoren bei der Diagnose und Behandlung mitgeteilt.

Methodik: Retrospektiv werden die Daten von 21 Kindern im Alter von 6,3–18 Jahren und Jugendlichen mit NCC analysiert, die zwischen 1992 und 2009 an polnischen kinderonkologischen Zentren behandelt wurden.

Ergebnisse: 2 Patienten entwickelten das NCC als Zweittumor nach Neuroblastom bzw. fibrillärem Astrozytom. Bei 6 Patienten wurde radiologisch zuerst ein Wilms-Tumor diagnostiziert und präoperativ chemotherapiert; die anderen 15 Patienten wurden primär operiert. Die Stadien nach dem AJCC/TNM-System waren: Stadium I n=14, Stadium II n=5, Stadium III n=1, Stadium IVn=1. Bei 19 Patienten erfolgte eine Nephrektomie, je ein Patient wurde heminephrektomiert bzw. biopsiert. Die histopathologischen Diagnosen waren: klarzelliges NCC n=18, papillares NNC n=2 und chromophobes NCC n=1. 10 Patienten wurden chemotherapeutisch behandelt, zum Teil in Kombination mit IL-2, IFNα und antiangiogenetischer Therapie. 2 Patienten sind an Tumorprogression verstorben.

Schlussfolgerung: Bei den meisten Kindern ist ein NCC operabel, die Prognose nach kompletter Resektion ist gut. Die Rolle einer adjuvanten Therapie ist unklar. Die präoperative Chemotherapie für Wilms-Tumoren zeigte keinen therapeutischen Effekt.

Supplementary Material

References

  • 1 Aktar M. Broadening spectrum of renal cell carcinoma in children and young adults.  Adv Anat Pathol. 2005;  12 37-38
  • 2 Barrantes JC, Muir KR, Toyn CE. et al . Thirty-year population-based review of childhood renal tumours with an assessment of prognostic features including tumour DNA characteristics.  Med Pediatr Oncol. 1993;  21 24-30
  • 3 Brinkmann OA, Bruns F, Prott FJ. et al . Possible of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).  Anticancer Res. 1999;  19 1583-1587
  • 4 Bruder E, Passera O, Harms D. et al . Morphologic and molecular characterization of renal cell carcinoma in children and young adults.  Am J Surg Pathol. 2004;  28 1117-1132
  • 5 Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma.  Mod Pathol. 2009;  22 24-36
  • 6 Eble JN, Sauter G, Epstein JI. et al .(Ed.) Tumors of the kidney.. In: World Health Organization Classification of Tumours: Tumours of the urinary system and male genital organs Lyon, France: IARC Press; 2004: 9-87
  • 7 Estrada CR, Suthar AM, Eaton SH. et al . Renal cell carcinoma: Children's Hospital Boston experience.  Urology. 2005;  66 1296-1300
  • 8 Frank I, Blute ML, Leibovich BC. et al . pT2 classification for renal cell carcinoma. Can its accuracy be improved?.  J Urol. 2005;  173 380-384
  • 9 Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma.  Cancer. 2004;  101 1575-1583
  • 10 Gez E, Rubinov R, Gaitini D. et al . Interleukin-2, interferon-alfa, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996–2000.  Cancer. 2002;  95 1644-1649
  • 11 Graf N, Hoppe A, Georgiadi E. et al . ‘In Silico’ oncology on clinical decision making in the context of nephroblastoma.  Klin Padiatr. 2009;  221 141-149
  • 12 Green FL, Page DL, Fleming ID. et al .AJCC Cancer Staging Manual.. 6th Edn. Springer: New York; 2002
  • 13 Hatcher PA, Anderson EE, Paulson DF. et al . Surgical management and prognosis of renal cell carcinoma invading the vena cava.  J Urol. 1991;  145 20-23
  • 14 Helmy T, Sarhan O, Sarhan N. et al . Renal cell carcinoma in children: single-center experience.  J Ped Surg. 2009;  44 1750-1753
  • 15 Huang FS, Zwerdling T, Stern LE. et al . Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia.  J Pediatr Hematol Oncol. 2001;  23 609-611
  • 16 Indolfi P, Terenziani M, Casale F. et al . Renal cell carcinoma in children: a clinicopathologic study.  J Clin Oncol. 2003;  21 530-535
  • 17 Jayasinghe C, Siegler N, Leuschner I. et al . Renal cell carcinoma with Xp11.2 translocation in a 7-year-old boy.  Klin Padiatr. 2010;  222 187-189
  • 18 Jemal A, Siegel R, Ward E. et al . Cancer statistics, CA.  Cancer J Clin. 2007;  57 43-46
  • 19 Keeller LL, Klaubert GT. Von Hippel-Lindau disease and renal cell carcinoma a 16-year-old boy.  J Urol. 1992;  147 1588-1591
  • 20 Kluger HM, Siddiqui SF, Angeletti C. et al . Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells.  Lab Invest. 2008;  88 962-972
  • 21 Lam JS, Breda A, Belldegrun AS. et al . Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma.  J Clin Oncol. 2006;  24 5565-5575
  • 22 Lonergan GJ, Martinez-Leon MI, Agrons GA. et al . Nephrogenic rests, nephroblastomatosis, and associated lesions of the kidney.  RadioGraphics. 1998;  18 947-968
  • 23 Margulis V, Tambilo P, Matin SF. et al . Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.  Cancer. 2008;  112 1480-1488
  • 24 Parekh DJ, Cookson MS, Chapman W. et al . Renal cell carcinoma with renal vein and inferior vena cava involvement: clinicopathological features, surgical techniques and outcomes.  J Urol. 2005;  173 1897-1902
  • 25 Pastore G, Znaor A, Spreafico F. et al . Malignant renal tumour incidence and survival in European children (1978–1997): report from the ACCIS project.  Eur J Cancer. 2006;  42 2103-2114
  • 26 Plantade A, Rini B, Negrier S. et al . Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib.  J Clin Onc. 2007;  25 5037
  • 27 Schneider DT, Brecht IB. Care for rare cancers: Improved care requires improved communication.  Klin Padiatr. 2010;  222 124-126
  • 28 Selle B, Furtwangler R, Graf N. et al . Population-based study of renal cell carcinoma in children in Germany, 1980–2005.  Cancer. 2006;  107 2906-2914
  • 29 Terrone C, Cracco C, Porpiglia F. et al . Reassessing the current TNM lymph node staging for renal cell carcinoma.  Eur Urol. 2006;  49 324-331
  • 30 Vasselli JR, Yang JC, Linehan WM. et al . Lack of retroperitoneal lympadenopathy predicts survival of patients with metastatic renal cell carcinoma.  J Urol. 2001;  166 68-72

Correspondence

Dr. Teresa Stachowicz-StencelMD, PhD 

Medical University of Gdansk

Department of Pediatrics,

Hematology,

Oncology and Endocrinology

7 Debinki Street

80–286 Gdansk

Poland

Phone: +48/583 492 880

Fax: +48/583/492 847

Email: tsten@gumed.edu.pl

>